Investment ThemesDetailed Quotes
Cancer Research
Watchlist
Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
- 1114.235
- +2.873+0.26%
Trading Jan 15 15:34 ET
1121.420High1111.001Low
1115.718Open1111.362Pre Close40.16MVolume5Rise28.43P/E (Static)2.13BTurnover--Flatline0.29%Turnover Ratio866.71BMarket Cap4Fall856.46BFloat Cap
Constituent Stocks: 9Top Rising: ARAY+4.32%
Sign in to post a comment
$Pfizer (PFE.US)$ How come whole market up Youre down
2
$Esperion Therapeutics (ESPR.US)$ The current stock price doesn't justify the incredible growth prospects this company has. Esperion sells the only FDA labeled Statin alternative drugs with primary prevention labels, script growth is growing rapidly and Esperion will be profitable in 2025 with expected $0.25 per share in earnings and $0.70c per share in 2026, which makes E...
9
4
$Pfizer (PFE.US)$
Pfizer Has Sold 700 Mln Ordinary Shares in Haleon at a Price of 357 Pence per Ordinary Share - Bookrunner
Pfizer Has Raised Gross Sale Proceeds of About £2.50 Bln - Bookrunner
Pfizer Has Sold 700 Mln Ordinary Shares in Haleon at a Price of 357 Pence per Ordinary Share - Bookrunner
Pfizer Has Raised Gross Sale Proceeds of About £2.50 Bln - Bookrunner
1
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Pfizer (PFE.US)$
MooMoo 2025 Angbao Draw
MooMoo 2025 Angbao Draw
1
$Pfizer (PFE.US)$
According to Zhitong Finance APP, Pfizer's CEO Albert Bourla stated on Monday at the JPMorgan Medical Care Conference that the company is "All in" in developing its experimental weight loss drug and has been recruiting more experts in this field.
Bourla mentioned that experts are helping Pfizer make "better and more rational decisions," and that the company may initiate late-stage research on its drug danuglipron in the second half of this year.
Pfizer is testing a multi-dose we...
According to Zhitong Finance APP, Pfizer's CEO Albert Bourla stated on Monday at the JPMorgan Medical Care Conference that the company is "All in" in developing its experimental weight loss drug and has been recruiting more experts in this field.
Bourla mentioned that experts are helping Pfizer make "better and more rational decisions," and that the company may initiate late-stage research on its drug danuglipron in the second half of this year.
Pfizer is testing a multi-dose we...
1
3
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
53
20
9
, today announced it has wrapped up its presence at the 2025 Consumer Electronics Show (CES) and achieved key strategic milestones. The culmination of the event demonstrates that the company is poised to deliver exceptional value to its customers.$Accuray (ARAY.US)$
Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
Monday, 13th January at 3:00 pm
MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Adm...
Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
Monday, 13th January at 3:00 pm
MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Adm...
1
3
No comment yet
Bushky : something needs to happen. between now and 2028. I'm betting on bird flu or some fat drug. to make this pop hopefully in the next 6 months.
Own Nvda Aiproducts : Trash of trash